Advanced science education in the regulatory arena: The Center for Drug Evaluation and research experience at the Food and Drug Administration

被引:0
|
作者
Ajayi, FO [1 ]
Wilcox, DF [1 ]
Uhl, K [1 ]
Quinn, J [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2002年 / 42卷 / 07期
关键词
D O I
10.1177/009127002401102650
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A challenge faced by the Center for Drug Evaluation and Research (CDER) in effectively carrying out its mission requires it to integrate the disciplines of science, medicine, law, and public policy. One way to do that is by ensuring a highly trained multidisciplinary staff, The CDER has been able to meet this requirement by identifying the core competencies needed to accomplish its mission. The use of a competency-based training model in the planning, development, and delivery of its advanced scientific education program allows CDER staff to maintain current knowledge as well as prepare for future scientific education needs, The CDER educational model could be readily adopted to meet the educational needs of other organizations. (C) 2002 the American College of Clinical Pharmacology.
引用
收藏
页码:711 / 717
页数:7
相关论文
共 50 条
  • [31] The food and drug administration office of Women's Health: Impact of science on regulatory policy
    Obias-Manno, Dulce
    Scott, Pamela E.
    Kaczmarczyk, Joseph
    Miller, Margaret
    Pinnow, Ellen
    Lee-Bishop, Lynda
    Jones-London, Michelle
    Chapman, Kennerly
    Kallgren, Deborah
    Uhl, Kathleen
    JOURNAL OF WOMENS HEALTH, 2007, 16 (06) : 807 - 817
  • [32] Science is alive and well at the food and drug administration
    Schultz, DG
    Wagner, RF
    Campbell, G
    RADIOLOGY, 1997, 202 (02) : 317 - 318
  • [33] The Food and Drug Administration's Regulation of Tobacco The Center for Tobacco Products' Office of Science
    Ashley, David L.
    Backinger, Cathy L.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2012, 43 (05) : S255 - S263
  • [34] The US Food and Drug Administration and probiotics: Regulatory categorization
    Degnan, Frederick H.
    CLINICAL INFECTIOUS DISEASES, 2008, 46 : S133 - S136
  • [35] REGULATORY ASPECTS OF TERATOLOGY - ROLE OF THE FOOD AND DRUG ADMINISTRATION
    KELSEY, FO
    TERATOLOGY, 1982, 25 (02) : 193 - 199
  • [36] Introduction to the food and drug administration (FDA) regulatory process
    Hackett, JL
    Gutman, SI
    JOURNAL OF PROTEOME RESEARCH, 2005, 4 (04) : 1110 - 1113
  • [37] Regulatory Action on Rosiglitazone by the US Food and Drug Administration
    Woodcock, Janet
    Sharfstein, Joshua M.
    Hamburg, Margaret
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (16): : 1489 - 1491
  • [38] ArrayTrack - Supporting toxicogenomic research at the US Food and Drug Administration national Center for Toxicological Research
    Tong, WD
    Cao, XX
    Harris, S
    Sun, HM
    Fang, H
    Fuscoe, J
    Harris, A
    Hong, HX
    Xie, Q
    Perkins, R
    Shi, LM
    Casciano, D
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2003, 111 (15) : 1819 - 1826
  • [39] Interdisciplinary Education: The Advanced Science Research Center
    Brumberg, Joshua C.
    Gray, Annette C.
    ISCIENCE, 2020, 23 (02)
  • [40] Considerations for Clinical Review of Cellular Therapy Products: Perspectives of the China Food and Drug Administration Center for Drug Evaluation
    Liu, Yantong
    Zhao, Chenyang
    Gao, Liucun
    Yang, Huan
    He, Ruyi
    Gao, Chenyan
    HUMAN GENE THERAPY, 2018, 29 (02) : 121 - 127